China Orbital Atherectomy Market Size & Outlook, 2026-2034
China Orbital Atherectomy Market Insights
- According to Reed Intelligence analysis, the China Orbital Atherectomy Market size was USD 95.39 Million in 2025 and is projected to reach USD 213.82 Million by 2034.
- The China market is projected to grow at a CAGR of 9.36% between 2026 and 2034.
- By segment, Coronary Artery Disease emerged as the largest Application in terms of market size in 2025.
- Coronary Artery Disease is anticipated to remain the most attractive Application segment, recording the fastest growth during the forecast period.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- China accounted for 9.08% of the global Orbital Atherectomy Market size in 2025.
- By 2034, United States is expected to remain the top global market in terms of size.
- Within Asia Pacific, China is forecasted to dominate the regional Orbital Atherectomy Market size by 2034.
- Singapore will be the fastest-growing market in Asia Pacific, projected to achieve USD 14.5 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 95.39 Million |
| Market Size In 2034 | USD 213.82 Million |
| Largest segment | Coronary Artery Disease |
| Units | Revenue in USD Million |
| CAGR | 9.36% (2026-2034) |
| Segmnetation Covered | |
| Application |
|
| Product Type |
|
| End-Use |
|
| End-User Specialty |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
China Orbital Atherectomy Market Application 2026-2034 (USD Million)
| Application | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Coronary Artery Disease | XX.x | XX.x | XX.x | 59.45 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Peripheral Artery Disease | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
China Orbital Atherectomy Market Product Type 2026-2034 (USD Million)
| Product Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Orbital Atherectomy Systems | XX.x | XX.x | XX.x | 55.87 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Accessories Consumables | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
China Orbital Atherectomy Market End-Use 2026-2034 (USD Million)
| End-Use | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | XX.x | XX.x | XX.x | 44.3 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Ambulatory Surgical Centers | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Specialty Clinics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
China Orbital Atherectomy Market End-User Specialty 2026-2034 (USD Million)
| End-User Specialty | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interventional Cardiology | XX.x | XX.x | XX.x | 61.49 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Vascular Surgery | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
